The Washington Post: Breaking news: The Food and Drug Administration granted approval to a closely watched Alzheimer’s drug, concluding that the benefits of modestly slowing progression of the devastating disease outweigh its risks, drugmaker Eli Lilly announced.

Breaking news: The Food and Drug Administration granted approval to a closely watched Alzheimer’s drug, concluding that the benefits of modestly slowing progression of the devastating disease outweigh its risks, drugmaker Eli Lilly announced.

FDA approves Alzheimer’s drug donanemab after months of delaywww.washingtonpost.com The agency determined that the potential of slowing the devastating disease in patients with mild cognitive impairment outweigh the risks of brain bleeds.

These days, Derek is the preeminent drug discovery blogger in the world (not kidding) and his take is "we'll see," with a mix of slight optimism and clear recognition of significant side effects. www.science.org/content/blog...

Lilly's Alzheimer's Data for Donanemabwww.science.org

Bear in mind that the pathway of "Alzheimer's drugs" is littered with failures, some well intentioned, most fraudulent. Anyone that actually produces benefits that exceed negative side effects would be revolutionary.

если все так плохо, можете хотя бы знак подать? "Красного рассвета" кадры тоже вырежет?

Our society must learn to let go. Stop holding on to what is not. Moral courage is absent. Let them go.